Open AccessEnhanced Tumor Localization of Monoclonal Antibody by Treatment with Kininase II Inhibitor and Angiotensin II
Author(s) -
Noguchi Akinori,
Takahashi Toshio,
Yamaguchi Toshiharu,
Kitamura Kazuya,
Noguchi Akira,
Tsurumi Hiroshi,
Takashina Kenichiroh,
Maeda Hiroshi
Publication year - 1992
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1992.tb00093.x
Subject(s) - enalapril , monoclonal antibody , enzyme inhibitor , angiotensin ii , angiotensin converting enzyme , ace inhibitor , enalaprilat , renin–angiotensin system , pharmacology , chemistry , chemotherapy , antibody , medicine , endocrinology , enzyme , immunology , receptor , biochemistry , blood pressure
The effect of kininase II inhibitor, enalapril, on the delivery of monoclonal antibody A7 to the targeted tumor was investigated using athymic mice bearing human colon cancer, SVV1116. Enalapril alone, which enhances tumor vascular permeability through the kinin‐generating cascade, did not increase the uptake of 125 I‐labeled A7 ( 125 I‐A7) in SW1116 due to the systemic hypotension induced by its inhibitory effect on angiotensin converting enzyme. However, with combined angiotensin II (AT‐II) and enalapril treatment, a 2‐fold increase in the accumulation of 125 I‐A7 was seen when compared to A7 alone. This marked increase was presumably due to increased tumor vascular permeability induced by enalapril combined with the absence of hypotension due to the actions of AT‐II. This approach might be useful in radioimmunodetection and immunotargeting chemotherapy using monoclonal antibody.